180 258

Cited 3 times in

Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer

DC Field Value Language
dc.contributor.author박승우-
dc.contributor.author박정엽-
dc.contributor.author방승민-
dc.contributor.author정문재-
dc.contributor.author조중현-
dc.contributor.author송시영-
dc.contributor.author김소정-
dc.contributor.author이희승-
dc.contributor.author성민제-
dc.date.accessioned2022-12-22T03:48:26Z-
dc.date.available2022-12-22T03:48:26Z-
dc.date.issued2022-09-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/191988-
dc.description.abstractSome BTC types respond to pembrolizumab, but there are no known prognostic factors to predict its treatment benefits. In this study, we attempted to identify the prognostic factors associated with pembrolizumab as a second-line treatment for gemcitabine-refractory BTC. This retrospective and single tertiary-center study involved all the consecutive patients (n = 80) with refractory advanced BTC, who were diagnosed as programmed cell death ligand 1-positive and treated with pembrolizumab between August 2017 and February 2021. The overall survival (OS) was analyzed using Cox regression analysis. The median OS was 6.0 months [95% confidence interval (CI): 3.87-8.20]; median progression-free survival was 1.9 months (95% CI: 1.82-1.98); and the response rate was 15.9%. In the multivariate Cox regression analysis, the TB [adjusted hazard ratio (HR) = 2.286; 95% CI: 1.177-4.440; p = 0.015), albumin levels (adjusted HR = 0.392; 95% CI: 0.211-0.725; p = 0.003), ALP levels (adjusted HR = 1.938; 95% CI: 1.105-3.400; p = 0.021), and LMR (adjusted HR = 0.325; 95% CI: 0.173-0.609; p < 0.001) were identified as significant variables associated with the OS. High albumin levels and LMR and low ALP levels and TB were significantly associated with better OS in patients treated with pembrolizumab.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherMDPI-
dc.relation.isPartOfCANCERS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titlePrognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorChan Su Park-
dc.contributor.googleauthorMin Je Sung-
dc.contributor.googleauthorSo Jeong Kim-
dc.contributor.googleauthorJung Hyun Jo-
dc.contributor.googleauthorHee Seung Lee-
dc.contributor.googleauthorMoon Jae Chung-
dc.contributor.googleauthorSeungmin Bang-
dc.contributor.googleauthorSeung Woo Park-
dc.contributor.googleauthorSi Young Song-
dc.contributor.googleauthorJeong Youp Park-
dc.identifier.doi10.3390/cancers14174323-
dc.contributor.localIdA01551-
dc.contributor.localIdA01647-
dc.contributor.localIdA01786-
dc.contributor.localIdA03602-
dc.contributor.localIdA03912-
dc.contributor.localIdA02035-
dc.contributor.localIdA06335-
dc.contributor.localIdA03349-
dc.relation.journalcodeJ03449-
dc.identifier.eissn2072-6694-
dc.identifier.pmid36077857-
dc.subject.keywordadvanced biliary tract cancer-
dc.subject.keywordpembrolizumab-
dc.subject.keywordprognostic factor-
dc.contributor.alternativeNamePark, Seung Woo-
dc.contributor.affiliatedAuthor박승우-
dc.contributor.affiliatedAuthor박정엽-
dc.contributor.affiliatedAuthor방승민-
dc.contributor.affiliatedAuthor정문재-
dc.contributor.affiliatedAuthor조중현-
dc.contributor.affiliatedAuthor송시영-
dc.contributor.affiliatedAuthor김소정-
dc.contributor.affiliatedAuthor이희승-
dc.citation.volume14-
dc.citation.number17-
dc.citation.startPage4323-
dc.identifier.bibliographicCitationCANCERS, Vol.14(17) : 4323, 2022-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.